1127-85-1

Basic information

• Product Name: 2,4-DICHLORO-5,6,7,8-TETRAHYDROQUINAZOLINE
• Synonyms: 2,4-DICHLORO-5,6,7,8-TETRAHYDROQUINAZOLINE
• CAS NO: 1127-85-1
• Molecular Formula: C₈H₈Cl₂N₂
• Molecular Weight: 189.044
• Mol File: 1127-85-1.mol

Chemical Properties

• Melting Point: 72-73 °C
• Boiling Point: 306.7 °C at 760 mmHg
• Flash Point: 168.1 °C
• Appearance: /
• Density: 1.466 g/cm³
• Vapor Pressure: 0.00137mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.77±0.20(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-5,6,7,8-TETRAHYDROQUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-5,6,7,8-TETRAHYDROQUINAZOLINE(1127-85-1)
• EPA Substance Registry System: 2,4-DICHLORO-5,6,7,8-TETRAHYDROQUINAZOLINE(1127-85-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 1127-85-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-5,6,7,8-tetrahydroquinazoline is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2,4-Dichloro-5,6,7,8-tetrahydroquinazoline serves as a crucial building block for the synthesis of agrochemicals. Its incorporation into these products aids in the development of effective solutions for pest control and crop protection, thereby supporting agricultural productivity and sustainability.

InChI:InChI=1/C7H6Cl2N2/c8-6-4-2-1-3-5(4)10-7(9)11-6/h1-3H2

Upstream product

• 34170-21-3 2-(methylthio)-5,6,7,8-tetrahydroquinazolin-4-ol 
• 41302-34-5 2-(methoxycarbonyl)cyclohexanone 
• 35042-48-9 5,6,7,8-tetrahydroquinazoline-2,4(1H,3H)-dione 
• 86-96-4 quinazoline-2,4-diol 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 35042-48-9 2,4-Dihydroxy-5,6,7,8-tetrahydroquinazoline 

Downstream Products

• 198275-03-5 5-chloro-2-phenyl-7,8,9,10-tetrahydro-1,2,4-triazolo[4,3-c]quinazolin-3-one 
• 769158-38-5 2-[(2-chloro-4-oxo-5,6,7,8-tetrahydroquinazolin-3(4H)-yl)-methyl]benzonitrile 
• 1620843-80-2 5-[[4-[N-(2,3-dimethyl-2H-indazol-6-yl)-N-methylamino]-5,6,7,8-tetrahydroquinazolin-2-yl]amino]-2-methyl-benzenesulfonamide 
• 1620843-82-4 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)amino]-5,6,7,8-tetrahydroquinazolin-2-yl]amino]-2-methyl-benzenesulfonamide 
• 1620059-24-6 3-[[4-[N-(2,3-dimethyl-2H-indazol-6-yl)-N-methylamino]-5,6,7,8-tetrahydroquinazolin-2-yl]amino]-benzenesulfonamide 
• 1620059-26-8 N²-(3,4-dimethoxyphenyl)-N⁴-(2,3-dimethyl-2H-indazol-6-yl)-N⁴-methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine 
• 1620059-27-9 N²-(3-bromophenyl)-N⁴-(2,3-dimethyl-2H-indazol-6-yl)-N⁴-methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine 
• 1620059-28-0 N²-(3-fluorophenyl)-N⁴-(2,3-dimethyl-2H-indazol-6-yl)-N⁴-methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine 
• 1620059-29-1 N²-(3-chloro-4-fluorophenyl)-N⁴-(2,3-dimethyl-2H-indazol-6-yl)-N⁴-methyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine 
• 76781-12-9 4-amino-2-(4-benzyl-1-piperazinyl)-5,6,7,8-tetrahydroquinazoline dihydrochloride 
• 76781-28-7 2-[4-(4-Methylphenyl)piperazino]-4-amino-5,6-tetramethylenepyrimidine 
• 76781-25-4 2-(4-Phenylpiperazino)-4-amino-5,6-tetramethylenepyrimidine 
• 76781-24-3 4-amino-2-<4-(p-toluenesulfonyl)piperazino>-5,6,7,8-tetrahydroquinazoline 
• 76781-23-2 4-amino-2-(4-benzylthiocarbamoylpiperazino)-5,6,7,8-tetrahydroquinazoline 

Relevant articles and documents

Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors

Valine-containing protein (VCP) is a member of the adenosine triphosphate family involved in a variety of cellular activities. VCP/p97 is capable of maintaining protein homeostasis and mediating the degradation of misfolded polypeptides by the ubiquitin–proteasome system (UPS). In this manuscript, a series of novel p97 inhibitors with pyrimidine as core structure were designed, synthesized and biologically evaluated. Based on the enzymatic results, a detailed structure–activity relationship discussion of the synthesized compounds was carried out. Furthermore, cellular activities of the compounds with enzymatic potency of less than 200 nM were investigated by using A549 and RPMI8226 cell lines. Among the screened inhibitors, compound 17 (IC50, 54.7 nM) showed good enzymatic activity. Investigation of cellular activities with non-small cell lung cancer A549 and multiple myeloma (MM) RPMI8226 further confirmed the potency of 17 with the IC50 values of 2.80 μM and 0.86 μM, respectively. Compound 17 is now being developed as a candidate. Finally, docking studies were carried out to explore the possible binding mode between the active inhibitor 17 and p97.

Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β

We disclose a novel class of 6-Amino-Tetrahydroquinazoline derivatives that inhibit human topoisomerase II (topoII), a validated target of anticancer drugs. In contrast to topoII-Targeted drugs currently in clinical use, these compounds do not act as topo

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several comp

PYRIDAZINIUM COMPOUNDS FOR USE IN CONTROLLING UNWANTED PLANT GROWTH

Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as herbicides.

KRAS G12C INHIBITORS AND USES THEREOF

The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

Synthesis and evaluation of novel fused pyrimidine derivatives as GPR119 agonists

A novel series of fused pyrimidine derivatives were designed, synthesized and evaluated as GPR119 agonists. Among them, cyclohexene fused compounds (tetrahydroquinazolines) showed greater GPR119 agonistic activities than did dihydrocyclopentapyrimidine and tetrahydropyridopyrimidine scaffolds. Analogues (16, 19, 26, 28, 42) bearing endo-N-Boc-nortropane amine and fluoro-substituted aniline exhibited better EC50 values (0.27–1.2 μM) though they appeared to be partial agonists.

4-AMINO-2-PYRIDO-BICYCLIC PYRIMIDINES AND USE THEREOF AS TOPOISOMERASE II INHIBITORS

The present invention concerns 4-amino-2-pyrido-bicyclic pyrimidines as type II topoisomerase inhibitors and use thereof as medicaments especially in the treatment of cancer. The invention also provides a method for the manufacture of 4- amino-2-pyrido bicyclic pyrimidines.

Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives

The invention belongs to the field of drug synthesis and relates to novel pyrimidine derivatives, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, preparation methods of thenovel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof and use of the novel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of therapeutic agents, particularly PAK inhibitors. The derivatives disclosed by the invention are represented by a general formula (I) or (II), wherein each substituent is as defined in claims.

Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof

The invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives and a use thereof. The above compounds and a medicinal composition containing the compounds are used for suppressing an orexin receptor. The invention also relates to a method for preparing the compounds and the medicinal composition, and the use of the compounds and the medicinal composition in the treatment or prevention of orexin receptor related diseases.